1. Pink Sheet
  3. >>Europe

UK Statutory Scheme Rebate Rise Could Cause Product Shortages & Launch Delays

 
• By Leela Barham

The pharmaceutical industry is calling on the government to take steps to restore the UK as a location for life sciences investment and recognize the role of competition in the branded generics market, but it will need strong evidence to make the most convincing case.

Close-up shot of pills with stamped pound sterling GBP symbol on them.
The statutory scheme is one way to govern drug prices in the UK • Source: Shutterstock

The latest proposed hike in rebates due from companies under the UK’s statutory scheme to control the costs of branded medicines is predicted to add further pressure on medicine supply and could even delay or even stop some product launches in the UK, industry sources have warned. 

The increase in the rebate under the statutory scheme is driven by a need to align with the higher rebate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US Policy Shift Sparks German Contingency Plans For Accessing ClinicalTrials.gov, PubMed

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 
• By Anju Ghangurde

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion

Best Laid Plans: A Chronology Of Post-Pandemic COVID-19 Vaccines

 
• By Bridget Silverman

Quick responses to late-breaking changes to US FDA COVID-19 vaccine policy kept Novavax's Nuvaxovid and Moderna's mNexspike close to expected approval timelines despite revised indications and new post-marketing trial commitments.